Heartland Advisors Inc. reduced its position in shares of Humana Inc. (NYSE:HUM – Free Report) by 10.6% in the first quarter, Holdings Channel reports. The fund owned 21,353 shares of the insurance provider’s stock after selling 2,535 shares during the quarter. Heartland Advisors Inc.’s holdings in Humana were worth $3,702,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Revolve Wealth Partners LLC bought a new stake in Humana in the fourth quarter worth $202,000. Woodline Partners LP lifted its position in Humana by 460.0% during the first quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock valued at $2,697,000 after purchasing an additional 8,372 shares during the last quarter. Sivia Capital Partners LLC grew its stake in shares of Humana by 53.7% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock worth $316,000 after buying an additional 452 shares in the last quarter. Cresset Asset Management LLC grew its stake in shares of Humana by 10.3% in the 2nd quarter. Cresset Asset Management LLC now owns 2,369 shares of the insurance provider’s stock worth $581,000 after buying an additional 222 shares in the last quarter. Finally, WINTON GROUP Ltd increased its holdings in shares of Humana by 58.5% in the 2nd quarter. WINTON GROUP Ltd now owns 2,381 shares of the insurance provider’s stock worth $582,000 after buying an additional 879 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.
Humana Price Performance
Shares of HUM stock opened at $400.51 on Monday. Humana Inc. has a 52-week low of $163.11 and a 52-week high of $428.88. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.77 and a current ratio of 1.77. The firm has a market capitalization of $48.09 billion, a P/E ratio of 42.84, a P/E/G ratio of 2.16 and a beta of 0.71. The stock has a 50 day moving average price of $354.03 and a 200 day moving average price of $260.20.
Analyst Ratings Changes
Several analysts have recently issued reports on HUM shares. Barclays upped their target price on shares of Humana from $180.00 to $344.00 and gave the company an “equal weight” rating in a research report on Tuesday, May 26th. Oppenheimer raised Humana from an “outperform” rating to an “outperform” rating in a research note on Wednesday, May 20th. Needham & Company LLC began coverage on Humana in a research report on Wednesday, May 20th. They set a “buy” rating on the stock. UBS Group reaffirmed a “neutral” rating on shares of Humana in a research note on Monday, June 15th. Finally, Guggenheim lifted their target price on Humana from $252.00 to $269.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $325.87.
About Humana
Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.
In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.
Featured Articles
- Five stocks we like better than Humana
- Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
- Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
- 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
